Table 1.
Disease demographics and management data
| Parameter | N (%) |
|---|---|
|
Age (median) |
62.6 years |
|
Gender (Female/Male) |
97 (43.0%)/129 (57.0%) |
|
Histological Grade |
|
| 1–2 |
170 (75.2%) |
| 3-4 |
46 (20.4%) |
|
Obstruction Yes/No |
30 (13.2%)/179 (79.2%) |
|
Perforation Yes/No |
9 (4.0%)/201 (89.0%) |
|
Primary Site Left/Right |
165 (73.0%)/60 (26.6%) |
| Rectum |
71 (31.0%) |
|
TNM stage at biopsy |
|
| I-III versus IV |
83 (36.8%)/137 (60.6%) |
|
Median Follow Up |
73.6 months |
|
Deaths |
175 (77.4%) |
|
Line of therapy at Cetuximab administration |
|
| 1st line |
38 (16.8%) |
| 2nd line |
108 (47.8%) |
| 3rd line and beyond |
80 (35.4%) |
|
Type of therapy at Cetuximab administration |
|
| Irinotecan-based |
153 (48.7%) |
| Oxaliplatin-based |
84 (26.7%) |
| Both irinotecan and oxaliplatin |
29 (9.2%) |
| Only fluoropyrimidine |
6 (1.9%) |
| Single-agent Cetuximab |
42 (13.4%) |
|
Objective Response to Cetuximab |
|
|
All lines of therapy |
|
| Complete Respone (CR) |
2 (0.9%) |
| Partial Response (PR) |
55 (24.4%) |
| ORR (CR+PR) |
57 (25.3%) |
| Stable disease (SD) |
66 (29.3%) |
| Progressive disease (PD) |
70 (31.1%) |
|
ORR by line of Cetuximab therapy |
|
| 1st line |
17 (44.7%) |
| 2nd line |
23 (21.5%) |
| 3rd line | 14 (22.9%) |